Medical Developments International (ASX:MVP) DeferredTaxAndRevenue: A$0.06 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MVP Medical Developments International Ltd ASX:MVP
54 GF Score
Price A$0.41
GF Value A$0.65
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medical Developments International DeferredTaxAndRevenue?

Medical Developments International ASX:MVP 54 DeferredTaxAndRevenue is A$0.06 Mil as of Dec. 2025. GuruFocus rates ASX:MVP with a GF Score™ of 54/100 and a GF Value™ of A$0.65 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Medical Developments International's current deferred tax and revenue for the quarter that ended in Dec. 2025 was A$0.06 Mil.

Medical Developments International DeferredTaxAndRevenue Related Terms

Medical Developments International DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Medical Developments International's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International DeferredTaxAndRevenue Chart

Medical Developments International Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.08 0.28 0.28 0.32

Medical Developments International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.28 0.00 0.32 0.06
ASX:MVP
54GF Score
Medical Developments International Ltd ASX:MVP
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of A$0.06 Mil mean?
Medical Developments International (ASX:MVP) has a DeferredTaxAndRevenue of A$0.06 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Medical Developments International.
Is Medical Developments International's DeferredTaxAndRevenue too high?
Medical Developments International's current DeferredTaxAndRevenue is A$0.06 Mil. Overall, Medical Developments International has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's DeferredTaxAndRevenue compare to ZTS and UTHR?
Medical Developments International's DeferredTaxAndRevenue of A$0.06 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Medical Developments International. Medical Developments International's current DeferredTaxAndRevenue is A$0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.65, compared to a current price of A$0.41 — trading 37.7% below its estimated fair value. The current DeferredTaxAndRevenue is A$0.06 Mil. Medical Developments International's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current DeferredTaxAndRevenue is A$0.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Developments International (ASX:MVP) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of A$0.41 is trading 37.7% below its estimated GF Value™ of A$0.65. GuruFocus considers Medical Developments International to be Significantly Undervalued.

Key valuation signals for ASX:MVP:

  • DeferredTaxAndRevenue: A$0.06 Mil
  • GF Value™: A$0.65 vs. price of A$0.41 (37.7% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medical Developments International Business Description

Other Exchanges MDDVF:USAM5D:Germany
Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
54GF Score

Get the complete analysis for ASX:MVP

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.41
Price
A$0.65
GF Value